Ovarian Reserve and Ankylosing Spondylitis

Completed

• Conditions: Anti-Mullerian Hormone Deficiency; Ovarian Diseases; Ankylosing Spondylitis

• Registration Number: NCT04209881
• Lead Sponsor: Kanuni Sultan Suleyman Training and Research Hospital

Brief Summary

The aim of this study was to determine the status of ovarian reserve in patients with ankylosing spondylitis (AS) using anti-mullerian hormone (AMH) level and antral follicle count (AFC). Women with AS and women controls diagnosed according to the classification criteria proposed by the American-European Consensus Group will be included in the study. Ovarian reserve will be evaluated in terms of clinical findings, AFC and serum AMH and reproductive hormone levels.

Researchers predict that the ovarian reserve may be reduced in patients with AS due to the autoimmune process and the pathophysiology of the disease. Serum AMH and ovarian AFC may be useful for assessing ovarian reserve. It is aimed to determine the course of ovarian reserve abnormalities and the best possible biomarkers of reduced ovarian reserve in patients with AS.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-19
• Study First Submitted: 2019-12-19
• Study First Submitted QC: 2019-12-21
• Study First Posted: 2019-12-24
• Status Verified: 2020-05
• Primary Completion: 2020-05-19
• Study Completion: 2020-05-19
• Last Update Submitted: 2020-05-21
• Last Update Posted: 2020-05-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

• regular menstruation with intervals of 21-35 days;
• cycle length variations <4 days;
• both ovaries still present

Exclusion Criteria

• history of liver failure;
• diagnosed malignancy;
• cigarette smoking;
• chronic renal failure;
• known infertility;
• presence of gynecological abnormalities such as abnormal uterine bleeding or menorrhagia;
• history of ovarian surgery;
• history of hormone preparation (including corticosteroids) use or use of herbal products within 3 months;
• diagnosis of polycystic ovary syndrome.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
anti-müllerian hormone (AMH)	3 days	For ovarian capacity AMH will be examined and AMH levels will be recorded in pmol/l
antral follicle count (AFC)	1 day	For ovarian capacity AFC will be examined and It will be recorded as a NUMBER.

Trial Locations

Locations (1)

Kanuni Sultan Süleyman Training and Research Hospital; 🇹🇷 Istanbul, Turkey